Lefra 20 Tablet contains Leflunomide 20 mg, an immunomodulatory agent primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide exerts its therapeutic effect by inhibiting dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammation and joint damage. This mechanism helps to alleviate symptoms such as joint pain, swelling, and stiffness, while also slowing disease progression. Lefra 20 is typically administered orally once daily, with dosage adjustments based on clinical response and tolerability. Prior to initiation, patients should be evaluated for liver function, as Leflunomide has been associated with hepatotoxicity; regular monitoring during treatment is recommended. It is contraindicated in pregnancy due to teratogenic potential and should be used with caution in patients with pre-existing liver or renal impairment. Common adverse effects include diarrhea, rash, alopecia, and mild gastrointestinal disturbances. Lefra 20 may interact with other immunosuppressants and hepatotoxic drugs, necessitating careful review of concomitant medications. Overall, Lefra 20 Tablet offers an effective option for managing autoimmune arthritis conditions by modulating immune response and reducing inflammatory activity.